SIC
AARD

SJS Investment Consulting’s Aardvark Therapeutics AARD Stock Holding History

SJS Investment Consulting’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93 Buy
16
+14
+700% +$65 ﹤0.01% 2627
2026
Q1 		$8 Buy
+2
New +$21 ﹤0.01% 2437

Other funds holding AARD

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SJS Investment Consulting's AARD Position: Q2 2026 in Review

SJS Investment Consulting increased its Aardvark Therapeutics (AARD) stake by 700% in Q2 2026, buying an estimated $65 and bringing the position to 16 shares worth $93. The position accounts for ﹤0.01% of the portfolio, ranked #2627.

SJS Investment Consulting first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • SJS Investment Consulting held 16 shares of Aardvark Therapeutics worth $93 as of Q2 2026.
  • SJS Investment Consulting bought 14 Aardvark Therapeutics shares in Q2 2026, an estimated $65.
  • Aardvark Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2627 holding.
  • SJS Investment Consulting first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.